Telix Pharmaceuticals Limited today announces that its prostate cancer PET[1] imaging agent Illuccix® (kit for the preparation of gallium-68 gozetotide injection) has been granted marketing ...

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that its prostate cancer PET[1] imaging agent Illuccix® ...

Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, April 14, 2025 /PRNewswire/ -- Equity Insider News Commentary - Routine medical ...

Semenax, manufactured by Leading Edge Health, is a supplement specifically designed to increase semen volume and intensify ...

Report Metric Details Base year considered 2023 Forecast period considered 2024-2029 Base year market size $9.

The hope is the therapy can effectively target cancerous cells at relatively small doses while minimizing side effects.

A new study provides the strongest evidence to date on the clinical utility of a polygenic score for prostate cancer ...

Metastatic castration-resistant prostate cancer (mCRPC) treatment can involves chemotherapy, radiation, and more. Find the ...

Metastatic castration-resistant prostate is an advanced form of the cancer that’s incurable. Learn about treatment options ...

Nearly all men with a polygenic risk score in the 90th percentile or above had a 10-year absolute risk for prostate cancer exceeding 3.8%. A polygenic risk score (PRS) identifies more patients with ...

In a Maple Grove industrial strip mall unequipped with the beanbag chairs common to Silicon Valley startups, Francis Medical ...

BALTIMORE, April 15, 2025 (GLOBE NEWSWIRE) -- The Urology Care Foundation, the world’s leading nonprofit urological health foundation and the official foundation of the American Urological Association ...